{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["2013"],"submitter":["Carbonell JL"],"pubmed_abstract":["Objectives. To evaluate the efficacy, safety, and quality of life by using 2.5 and mifepristone 5 mg daily doses to treat uterine fibroids over 3 months with a 9-month followup period. Design. Randomized clinical trial. Place. \"Eusebio Hernández\" Hospital, Havana, Cuba. Subjects. 220 women with symptomatic uterine fibroids. Treatment. One-half (2.5 mg) or one-whole 5 mg mifepristone tablet. Variables to Evaluate Efficacy. Changes in fibroid and uterine volumes, in symptomatic prevalence and intensity, and in quality of life. Results. After 3-month treatment, fibroid volume decreased by 27.9% (CI 95% 20-35) and 45.5% (CI 95% 37-62), in the 2.5 and 5 mg groups, respectively, P = 0.003. There was no difference in the prevalence of symptoms at the end of treatment, unlike after 6- and 9-month "],"journal":["ISRN obstetrics and gynecology"],"pagination":["649030"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3747426"],"repository":["biostudies-literature"],"pubmed_title":["Treatment of Uterine Myoma with 2.5 or 5 mg Mifepristone Daily during 3 Months with 9 Months Posttreatment Followup: Randomized Clinical Trial."],"pmcid":["PMC3747426"],"pubmed_authors":["Garces R","Carbonell JL","Sanchez C","Perez Y","Acosta R","Tomasi G"],"additional_accession":[]},"is_claimable":false,"name":"Treatment of Uterine Myoma with 2.5 or 5 mg Mifepristone Daily during 3 Months with 9 Months Posttreatment Followup: Randomized Clinical Trial.","description":"Objectives. To evaluate the efficacy, safety, and quality of life by using 2.5 and mifepristone 5 mg daily doses to treat uterine fibroids over 3 months with a 9-month followup period. Design. Randomized clinical trial. Place. \"Eusebio Hernández\" Hospital, Havana, Cuba. Subjects. 220 women with symptomatic uterine fibroids. Treatment. One-half (2.5 mg) or one-whole 5 mg mifepristone tablet. Variables to Evaluate Efficacy. Changes in fibroid and uterine volumes, in symptomatic prevalence and intensity, and in quality of life. Results. After 3-month treatment, fibroid volume decreased by 27.9% (CI 95% 20-35) and 45.5% (CI 95% 37-62), in the 2.5 and 5 mg groups, respectively, P = 0.003. There was no difference in the prevalence of symptoms at the end of treatment, unlike after 6- and 9-month ","dates":{"release":"2013-01-01T00:00:00Z","publication":"2013","modification":"2025-05-29T21:07:22.575Z","creation":"2025-05-29T21:07:22.575Z"},"accession":"S-EPMC3747426","cross_references":{"pubmed":["23984082"],"doi":["10.1155/2013/649030"]}}